Metastatic Osteosarcoma Study

Study of Natalizumab as a Single Agent in Children, Adolescents and Young Adults with Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

Study Purpose

The purpose of this study is to evaluate if Natalizumab can be used safely and effectively as immunotherapy in children, adolescent and young adult patients with pOS. Natalizumab is currently Food and Drug Administration (FDA) approved for the treatment of T-cell mediated autoimmune disorders. The study team will evaluate the safety and tolerability of Natalizumab as well as the clinical response associated with Natalizumab treatment and evaluate overall survival.

Who Can Participate

Participants between 5 and 30 years of age diagnosed with Pulmonary Metastatic Osteosarcoma (pOS) may be eligible for this study.

• CASE1718
• NCT03811886